RBC Capital MarketsUnclaimed
Host of Pathfinders in Biopharma.
1 Feed-stated
Counts Verified and Feed-stated credits: what a show's own feed states, or a confirmation backs. See the record
- Host
Claim this profile Add a creditIs this you? Claiming needs a free account. You sign in or join, then come straight back here.
This profile is unclaimed. PodSubs built it from public show feeds and credits. The person it is about has not reviewed it yet.
PodCred record
PodCred is the verified record of where RBC has worked and appeared. These credits come from the shows' own feeds and wait for people who were there to confirm them.
Worked with RBC on a show? This is where you give them credit.
Shows they work on now
1 show
Is an appearance missing?
People get invited back because someone remembered they were great. If you heard this person on a show and it is not listed here, add it. Your memory might be the reason they get their next invitation.
No account needed. Anyone can give a credit.
Experience, education, skills, and recommendations start empty. They fill in when RBC claims this profile.
Recommendations
No recommendations for RBC yet.
Recommendations open once RBC claims the profile.
Posts
No posts yet. Posts RBC shares on PodSubs, and what RBC publishes on Substack, YouTube and elsewhere, will show here.
Recent episodes
From the shows they work on now
What's driving biotech's latest rally?
Biotech has delivered one of its strongest rallies in years, fueled by a resurgence in M&A activity, improving sentiment and continued innovation. But as valuations rise and competition intensifies, investors are...
Dyne Therapeutics pioneers direct drug delivery to muscle and CNS
Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s...
4DMT targets global retina market with long-lasting genetic treatment
This episode of RBC Pathfinders in Biopharma explores how next-generation retinal gene therapies could transform treatment for patients with wet AMD and diabetic macular edema. CCBO of 4D Molecular Therapeutics, Chris...
Why the MFN price battle is heading for court, not legislature
The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC’s Global...
Big-value deals set the pace in healthcare M&A
Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At...
Is this finally the breakthrough moment for psychedelic therapies?
Psychedelics are poised for a breakthrough in mainstream psychiatry, with high interest among physicians and patients alike. But does the infrastructure exist to deliver these treatments, given the clinical supervision...
No biotech bubble – but can the sector’s rally persist through 2026?
Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities...
MindMed: Rethinking brain health with psychedelic therapy
Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and...
Funding the future of retinal health with Eyepoint
Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.
How Blackstone Life Sciences is bridging the innovation gap
Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways:...
